top of page

Antitrust Risk Is No Longer Theoretical: Why It Now Belongs in D&O Insurance Planning

  • Apr 30
  • 3 min read

Written by: Cottingham & Butler Food & Agribusiness Group



Executive Summary

Antitrust enforcement in the United States has entered a materially more aggressive phase—one that increasingly places directors and officers under personal scrutiny. Recent federal investigations reinforce a broader regulatory shift: antitrust risk is no longer limited to transformational mergers or a few headline industries. For boards and executive teams, the financial, operational, and personal consequences of an investigation now warrant proactive attention, particularly in how Directors & Officers (D&O) insurance programs are structured.



A More Aggressive Enforcement Environment

In April 2026, The Wall Street Journal reported that the U.S. Department of Justice (DOJ) Antitrust Division opened a criminal investigation into major beef processors, examining whether highly concentrated market participants engaged in unlawful coordination affecting pricing and market behavior. While the companies involved have not been accused of wrongdoing—and investigations do not always result in charges—the inclusion of criminal prosecutors alongside civil enforcement signals an escalation that should not be ignored.


This case reflects a broader enforcement posture driven by:

  1. Industry consolidation and market concentration

  2. Price volatility and cost sensitivity for consumers

  3. Increased political and public attention on competition


For leadership teams, the key risk is not limited to eventual outcomes. The existence of a government investigation alone can trigger substantial legal expense, reputational pressure, and executive distraction.


Understanding Modern Antitrust Exposure

At its core, antitrust law is designed to preserve fair competition and prevent restraints on trade. Common areas of scrutiny include price‑fixing, bid‑rigging, market allocation, and other forms of coordinated conduct under the Sherman Antitrust Act.


What has changed is enforcement emphasis. Historically, antitrust actions were often civil and targeted primarily at corporate entities. Today, regulators are increasingly focused on individual accountability, examining whether directors and officers:

  1. Authorized or endorsed certain practices

  2. Failed to oversee pricing, data sharing, or competitor interaction

  3. Lacked sufficient governance controls or compliance oversight


Criminal antitrust matters can carry severe penalties for organizations. For individuals, the risk includes prolonged investigations, personal defense costs, and—at the extreme—criminal exposure. Even where no wrongdoing ultimately exists, investigations themselves are often long‑running and costly.


Where D&O Insurance Fits — and Where Risk Often Goes Unaddressed

D&O insurance is designed to protect directors and officers from claims alleging wrongful acts in the management of the organization, including regulatory investigations. However, antitrust exposure is one of the most nuanced and unevenly addressed risks within D&O programs.


Across the market, antitrust risk is typically handled in one of three ways:

  1. Specific endorsements or sublimits providing defined defense‑cost protection

  2. Restrictions on entity coverage, particularly for public companies

  3. Exclusions that limit coverage unless individuals are named


Even when exclusions appear broad, many policies continue to cover defense costs for individual directors and officers until a final adjudication establishes intentional or criminal misconduct. This is a critical distinction, as antitrust investigations can generate millions of dollars in defense expense long before liability is determined.


Programs that lack clarity around these provisions may leave executives unexpectedly exposed during the earliest and most expensive phase of an inquiry.


Why This Matters Now — Beyond Any One Industry

While recent enforcement activity has focused on food and agriculture, the underlying dynamics apply across many sectors. Companies are increasingly vulnerable to scrutiny where there is:

  1. Significant market share or pricing influence

  2. Benchmarking, information‑sharing, or industry collaboration

  3. Heightened regulatory or political sensitivity


As a result, antitrust risk should be viewed as a governance issue, not simply a legal one. For boards and executive management, the more relevant questions are:

  1. Are we prepared for the cost and disruption of a government investigation?

  2. Does our D&O program clearly address antitrust defense and individual protection?

  3. Have we assessed how our coverage would respond in the first 30 days of regulatory scrutiny?


Early clarity can materially affect outcomes—for both the organization and its leadership.


Conclusion

Antitrust risk is no longer a remote legal concept reserved for Silicon Valley or mega‑mergers. It is a mainstream exposure tied to scale, governance, and market dynamics. As enforcement becomes more aggressive and more personal, D&O insurance remains one of the few tools available to protect directors and officers during periods of heightened scrutiny.

For that protection to be effective, antitrust coverage must be an intentional and informed component of every D&O discussion—not a footnote. Proactive review today can help ensure leadership is protected when scrutiny inevitably arises.

bottom of page